Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

BACKGROUND: The live attenuated tetravalent dengue vaccine (CYD-TDV) is licensed using a 0-, 6- and 12-month schedule in dengue-endemic areas. An effective shorter schedule may provide more rapid, optimal protection of targeted populations during vaccine campaigns in dengue-endemic countries. We com...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirstein, Judith, Douglas, William, Thakur, Manoj, Boaz, Mark, Papa, Thomas, Skipetrova, Anna, Plennevaux, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150954/
https://www.ncbi.nlm.nih.gov/pubmed/30241510
http://dx.doi.org/10.1186/s12879-018-3389-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150954/
https://www.ncbi.nlm.nih.gov/pubmed/30241510
http://dx.doi.org/10.1186/s12879-018-3389-x

Ejemplares similares